Search this site

From emotional support and integrative oncology to metastatic breast cancer research, financial assistance, and clinical trial access, four nonprofit leaders discuss what it will take to build a more connected system of cancer care. Laura Carfang, Ed.D., Editorial COMMUNITY | PODCAST Key Takeaways Excellent medical treatment isn’t the same as comprehensive care. The needs that fall outside a clinical appointment — emotional, practical, financial — are central to the cancer experience, not extras. The problem isn’t missing resources — it’s fragmented access. Whether someone gets support too often depends on where they live, where they’re treated, and whether they know to ask. Emotional and peer support shouldn’t depend on your cancer center. Personalized, stage-specific connection reaches places clinical expertise alone can’t. Whole-person care is still priced like a luxury. When integrative and supportive services aren’t covered by insurance, access splits along financial lines — and quality of life shouldn’t. Metastatic breast cancer needs both research and dedicated support. As METAvivor’s Dr. Kelly Shanahan put it, “I live because of research” — and living well also requires stage-specific community and navigation. The biggest opportunity is connecting what already exists. No single organization can do it all; stronger partnerships, referrals, and sustained investment in nonprofits are how the system improves. A breast cancer diagnosis sets an entire medical system into motion. There are imaging appointments, pathology reports, treatment plans, surgeries, medications, and follow-up visits. Oncologists, surgeons, nurses, and other specialists work to deliver increasingly sophisticated treatments, informed by decades of research and medical innovation. But what happens to the needs that don't fit neatly into a medical appointment? Who helps someone navigate the emotional impact of a diagnosis? Who addresses the financial strain of traveling to treatment, the difficulty of managing persistent side effects, or the challenge of finding a support community that understands their particular experience? And who helps patients find these resources when they're already overwhelmed by everything else? These questions reveal an important distinction: Receiving excellent medical treatment is not the same as having access to comprehensive cancer care. To explore these gaps, SurvivingBreastCancer.org brought together four nonprofit leaders for a special episode of Breast Cancer Conversations: Laura Carfang, Co-Founder and CEO of SurvivingBreastCancer.org Ellen Friebert Schupper, Executive Director of After Breast Cancer Diagnosis (ABCD) Kelly Shanahan, MD, President of METAvivor Sue Weldon, Founder and CEO of Unite for HER Each organization serves the breast cancer community differently, from peer-to-peer emotional support and metastatic breast cancer research to integrative oncology, education, and community-based programs. Yet across these different missions, a common theme emerged: The problem isn't simply that supportive resources don't exist. It's that access to those resources remains fragmented, inconsistent, and often dependent on where someone lives, receives treatment, or knows to look. Here are five gaps that deserve greater attention and what it could take to close them. Listen now on the Podcast: Breast Cancer Conversations 1. Emotional Support Shouldn't Depend on Where You're Treated A cancer diagnosis changes more than someone's medical chart. It can alter relationships, employment, identity, family dynamics, and a person's sense of security about the future. Yet access to emotional and peer support varies considerably. Some cancer centers have established support programs and patient navigators. Others have limited resources. And even when support exists, patients may not know where to find it or may need something different from what's offered locally. For Ellen Friebert Schupper, Executive Director of After Breast Cancer Diagnosis (ABCD), this is precisely why personalized one-on-one peer support matters. ABCD specializes in connecting people affected by breast cancer with trained mentors who can offer one-to-one emotional support grounded in lived experience. This type of connection fills a need that clinical expertise, however valuable, cannot always address. Someone newly diagnosed may want to speak with another person who remembers the uncertainty of those first appointments. Someone experiencing difficult treatment side effects may need reassurance that their concerns deserve to be heard. A person living with metastatic breast cancer may want a peer mentor where conversations about progression, ongoing treatment, and uncertainty are understood. During the roundtable, METAvivor President Kelly Shanahan shared the organization's origins: women living with metastatic breast cancer who found that an existing support group was not prepared to accommodate their experiences. Rather than abandon their need for community, they created their own. Their efforts eventually helped build an organization dedicated to metastatic breast cancer research, advocacy, and support. The lesson extends well beyond any one diagnosis or organization. Support must be responsive to the person seeking it and not limited by what a particular institution or organization happens to offer. This is also why partnerships matter. SurvivingBreastCancer.org offers moderated support groups for different stages and experiences including early stage breast cancer, metastatic breast cancer, and inflammatory breast cancer to name a few, while ABCD specializes in individual mentor matching. These services complement one another rather than compete. 2. Whole-Person Cancer Care Remains Out of Reach for Too Many People Cancer treatment is designed to treat the disease. But the effects of cancer and its treatment can extend into nearly every aspect of daily life. Fatigue, sleep disturbances, anxiety, pain, changes in physical functioning, and other symptoms may persist during treatment and beyond. These concerns deserve attention as part of comprehensive cancer care. Evidence-informed supportive approaches including exercise, nutrition counseling, psychosocial interventions, and selected integrative therapies can help address particular symptoms and quality-of-life concerns. The evidence and recommendations differ by intervention and symptom, making individualized guidance important. Yet access is far from universal. Sue Weldon, Founder and CEO of Unite for HER, experienced this gap firsthand following her own breast cancer diagnosis. While navigating treatment and its side effects, she sought complementary supportive services that were not readily integrated into her medical care. That experience ultimately shaped Unite for HER's mission: expanding access to integrative therapies and supportive resources for people affected by breast and ovarian cancers. As Sue explained during the conversation, the challenge isn't simply awareness. It's affordability. Many supportive services are not consistently covered by insurance, leaving patients to pay out of pocket or forgo them altogether. And when families are already managing medical expenses, lost wages, transportation costs, and other financial pressures, additional wellness services may feel impossible to prioritize. This creates an inequity: people with greater financial resources may be able to access supportive care that others cannot. Whole-person care should not be a luxury reserved for those who can afford it. At SurvivingBreastCancer.org, we're working to make whole-person support more accessible through free virtual wellness programming, including movement, mindfulness, and other evidence-informed practices designed to support physical and emotional well-being during and beyond treatment. The strongest model is one in which evidence-informed supportive care works alongside oncology treatment, helping people manage symptoms, maintain function, and improve quality of life. For healthcare systems, this raises an important question: If we recognize that quality of life matters during cancer treatment, how do we make the services that support it more consistently accessible? 3. Metastatic Breast Cancer Requires Sustained Research and Dedicated Support Scientific progress has transformed breast cancer treatment, with new therapies and increasingly personalized approaches expanding options for many patients. But metastatic breast cancer (MBC) remains an incurable disease requiring ongoing treatment and careful management. For Kelly Shanahan, this reality is both professional and deeply personal. A physician diagnosed initially with early-stage breast cancer, Kelly later developed metastatic disease. Treatment-related neuropathy affected her ability to continue practicing medicine, and she eventually found a renewed sense of purpose through advocacy and leadership at METAvivor. During the roundtable, she described the role research has played in her life with remarkable clarity: “I live because of research.” Her words underscore why continued investment in metastatic breast cancer research is essential. Research advances are not abstract scientific milestones. They can translate into additional treatment options, longer periods of disease control, and improved quality of life. But the needs of people living with metastatic breast cancer extend beyond new therapies. Patients may face treatment changes, progression, cumulative side effects, disruptions to employment, and the ongoing emotional weight of living with an incurable illness. They may also need stage-specific support that acknowledges these realities rather than minimizing or avoiding them. Kelly emphasized that metastatic breast cancer research, community, and advocacy are interconnected priorities. That perspective challenges a tendency to separate scientific progress from the daily experiences of people living with advanced disease. Better treatments matter. So does the ability to live well while receiving them. A more complete approach to metastatic breast cancer must support both goals. It must also recognize the importance of involving people living with MBC in decisions about research priorities, supportive care programs, and policies that directly affect their lives. 4. Cancer Navigation, Clinical Trials, and Specialized Care Are Still Too Difficult to Acce Cancer care is becoming more sophisticated. Treatment decisions may depend on tumor subtype, biomarkers, previous therapies, genetic information, and a rapidly evolving body of clinical evidence. These advances create important opportunities. They also make it increasingly difficult for patients to navigate the system without specialized guidance. During the roundtable, Kelly described traveling hundreds of miles to see specialists with expertise in metastatic breast cancer. Her experience highlights a broader access challenge. For someone living in a rural community, obtaining a second opinion may involve long drives, time away from work, childcare arrangements, transportation expenses, and logistical obstacles. For others, the barrier may be uncertainty about which specialist to see or whether a clinical trial is available. And for people receiving treatment at community cancer centers, access to disease-specific expertise may be limited by geography and resources. Clinical trials present another significant opportunity and also another potential gap. Patients may not know when to ask about a clinical trial, how eligibility is determined, or where studies are available and discussions about trials may happen inconsistently across care settings. As the panel discussed, clinical trials should not be framed solely as a last resort. Depending on the diagnosis and circumstances, they may be relevant at different points in care. But awareness alone is not enough. People diagnosed with breast cancer and living with metastatic disease also need practical help understanding options, identifying appropriate resources, and navigating the steps required to explore participation. This is where stronger cancer navigation could make a meaningful difference. Imagine a system in which someone diagnosed with breast cancer could easily access: Clear, understandable information about their diagnosis and treatment options Guidance on obtaining an appropriate specialist consultation or second opinion Information about clinical trials and how to discuss eligibility with their care team Referrals to emotional, financial, and supportive care services Help identifying resources that match their diagnosis, location, and individual needs Some of these services exist today. The challenge is making them easier to discover, access, and coordinate. Patients should not have to become experts in navigating healthcare systems simply to receive the support they need. Improving access will require collaboration among cancer centers, community oncologists, patient organizations, researchers, and industry partners. It will also require attention to rural communities, historically underserved populations, and people who face language, transportation, financial, or digital barriers. 5. The Financial Burden of Breast Cancer Extends Far Beyond Medical Bills When we discuss the cost of cancer, attention often centers on treatment expenses, insurance coverage, and prescription medications. But the financial impact of a diagnosis reaches much further. A person receiving treatment may need to travel regularly to appointments, purchase groceries while unable to work, arrange childcare, or cover household expenses while income is reduced. For people living with metastatic breast cancer, these challenges are lifelong. The roundtable highlighted direct financial assistance as an important unmet need, alongside better navigation and access to supportive services. This is particularly significant because financial hardship can affect more than a household budget. It can influence whether someone can reliably travel to appointments, access supportive services, or manage the practical demands of treatment. Nonprofit organizations play an important role in addressing these needs, but charitable assistance alone cannot eliminate the broader financial burden of cancer. At SurvivingBreastCancer.org, financial assistance for people living with metastatic breast cancer is one component of our commitment to whole-person support, helping address nonmedical needs such as transportation, food, and essential household expenses. These forms of assistance may appear separate from medical treatment, but they are deeply connected to the experience of receiving care. A treatment plan does not exist independently of someone's life. When we talk about access to cancer care, we must also talk about whether people can afford the everyday realities of getting that care. The Bigger Challenge: Connecting the Resources That Already Exist Perhaps the most important takeaway from this conversation was not any single gap but rather, the recognition that no organization, hospital, or healthcare professional can address every need independently. ABCD specializes in one-to-one emotional support. METAvivor focuses on metastatic breast cancer research, advocacy, and community. Unite for HER expands access to integrative therapies and supportive care. SurvivingBreastCancer.org brings together evidence-informed education, community, wellness programming, navigation resources, and financial assistance. These organizations have distinct missions, expertise, and models. And that is a strength. During the discussion, the leaders spoke openly about the importance of understanding where their organizations are uniquely positioned to contribute and where partnerships can better serve patients than duplicating existing programs. This approach requires a shift in how we think about the breast cancer support ecosystem. Rather than asking every organization to provide every service, we should be asking how to create more effective pathways between the services that already exist. That means building relationships across institutions, improving referral systems, sharing trusted resources, and making it easier for patients to understand their options. It also means recognizing that nonprofit programs require sustainable investment. Behind every free support group, educational webinar, peer mentor program, and patient assistance initiative are people, technology, training, infrastructure, and operational costs. Sustaining those services is part of sustaining access. If we want high-quality, reliable patient support to remain available, we must invest not only in individual programs but also in the organizations and systems that make those programs possible. What Should the Future of Breast Cancer Care Look Like The future of breast cancer care will undoubtedly be shaped by scientific breakthroughs. New therapies, improved diagnostics, biomarker-driven treatment decisions, and advances in clinical research will continue to influence how breast cancer is treated. But medical innovation is only part of the equation. Progress must also be measured by how effectively people can access care, understand their options, manage symptoms, maintain quality of life, and find meaningful support. That requires a broader definition of comprehensive cancer care. The question is not whether every organization can do more, it is whether, together, we can build a system that works better for the people depending on it. Because the goal is not simply to create more breast cancer resources. It is to make the right resources easier to find, easier to access, and more meaningfully connected to the care people receive. That is the opportunity in front of us and it is a conversation worth continuing. At SurvivingBreastCancer.org, we believe patients and families deserve clear, evidence-based information that helps them ask informed questions and feel more confident in conversations with their medical team. Disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are personal and should be made in partnership with your oncology team.

What people with HER2-positive metastatic breast cancer should know about TUKYSA, Herceptin, and Perjeta. SurvivingBreastCancer.org Editorial EDUCATION | HER2+ Key Takeaways The FDA approval of TUKYSA (tucatinib) with Herceptin (trastuzumab) and Perjeta (pertuzumab) gives some adults with HER2-positive metastatic breast cancer a new chemotherapy-free maintenance treatment option after initial therapy. In the HER2CLIMB-05 trial, this combination helped people go longer before their cancer grew or spread compared with Herceptin and Perjeta alone. This treatment will not be right for everyone, but it may be an important option to discuss with your oncology team. The U.S. Food and Drug Administration has approved a new use for TUKYSA (tucatinib) in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) for people living with HER2-positive metastatic breast cancer (MBC) or unresectable locally advanced HER2-positive breast cancer after initial treatment. In plain language, this means that some people with HER2-positive metastatic breast cancer may now have a new chemotherapy-free maintenance treatment option after their first phase of treatment. This approval is important because it may help some people living with metastatic breast cancer go longer before their cancer grows or spreads. Let’s start with the basics: What is HER2-positive breast cancer? HER2 is a protein that helps cells grow. In some breast cancers, the cancer cells make too much HER2, which can cause the cancer to grow and spread more quickly. This is called HER2-positive breast cancer. HER2-positive breast cancer is often treated with medicines that specifically target HER2. These include drugs such as: trastuzumab (Herceptin) pertuzumab (Perjeta) tucatinib (TUKYSA) These are called HER2-targeted therapies because they are designed to interfere with the HER2 signals that help cancer cells grow. What was approved? The FDA approved TUKYSA (tucatinib) to be used with Herceptin (trastuzumab) and Perjeta (pertuzumab) as a maintenance treatment for people living with HER2-positive metastatic or unresectable locally advanced breast cancer after initial treatment. This approval applies after a person has already received initial treatment with: Herceptin (trastuzumab) Perjeta (pertuzumab) a taxane chemotherapy, such as paclitaxel (Taxol) or docetaxel (Taxotere) and their cancer has grown or progressed during that first phase of treatment. What does “maintenance treatment” mean? Maintenance treatment is treatment given after an initial treatment has helped control the cancer. We can think of it this way: The first phase of treatment is often used to get the cancer under control. If the cancer is shrinking, stable or responding to the treatment, maintenance treatment may be used to help keep the cancer controlled for as long as possible. For HER2-positive metastatic breast cancer, maintenance treatment often includes Herceptin (trastuzumab) and Perjeta (pertuzumab). This new approval adds TUKYSA (tucatinib) to that maintenance approach for eligible patients. Why is this approval important? In the Phase 3 HER2CLIMB-05 clinical trial, people who received TUKYSA (tucatinib) with Herceptin (trastuzumab) and Perjeta (pertuzumab) went longer before their cancer grew or spread compared with people who received Herceptin and Perjeta without TUKYSA. The study found: People receiving the TUKYSA combination had a median of 24.9 months before the cancer grew or spread. People receiving Herceptin and Perjeta without TUKYSA had a median of 16.3 months before the cancer grew or spread. This means the TUKYSA combination added a median of 8.6 more months without disease progression. The treatment reduced the risk of cancer progression by about 36% in the study. What does “progression-free survival” mean? You may see the phrase progression-free survival, often shortened to PFS. Progression-free survival means the amount of time during and after treatment that the cancer does not grow or spread. It does not mean the cancer is cured. It means the treatment helped keep the cancer controlled for a period of time. In this trial, the TUKYSA combination helped people go longer before the cancer grew or spread. Is TUKYSA (tucatinib) chemotherapy? TUKYSA is not traditional chemotherapy. TUKYSA is an oral targeted therapy. It is a pill that targets HER2, a protein involved in the growth of some breast cancer cells. Pfizer describes TUKYSA as an oral HER2 tyrosine kinase inhibitor. Herceptin and Perjeta are also HER2-targeted treatments, but they are given differently. They may be given through an IV or as part of a fixed-dose injection option, depending on the treatment plan. This approval is being described as a chemotherapy-free maintenance option because it may allow eligible patients to continue HER2-targeted treatment after initial chemotherapy without staying on traditional chemotherapy during the maintenance phase. Who might this apply to? This approval may apply to people with: HER2-positive metastatic breast cancer HER2-positive unresectable locally advanced breast cancer no cancer progression after initial treatment with Herceptin, Perjeta, and a taxane chemotherapy Your oncology team can help determine whether this treatment is appropriate based on your diagnosis, prior treatment, cancer behavior, side effects, other health conditions, and personal goals. What side effects should patients know about? Pfizer reported that the most common side effects in the HER2CLIMB-05 trial included diarrhea, muscle and joint pain, liver-related lab abnormalities or liver toxicity, nausea, fatigue, rash, and vomiting. What should I ask my oncology team? If you are taking or considering TUKYSA, ask your care team: Am I currently in the induction or maintenance phase of treatment? What does maintenance therapy mean in my treatment plan? Would TUKYSA be an option for me? What are the possible benefits of adding TUKYSA? How will my liver function be monitored? What should I do if I develop diarrhea? What side effects should I report right away? How will we know if the treatment is working? How often will I need bloodwork? Could this interact with any other medicines I take? Are there reasons this treatment may not be right for me? How does this option fit with my goals and quality of life? At SurvivingBreastCancer.org, we believe patients and families deserve clear, evidence-based information that helps them ask informed questions and feel more confident in conversations with their medical team. Disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are personal and should be made in partnership with your oncology team.

Learn the latest in immunotherapy for breast cancer. Checkpoint inhibitors now come with years of survival data behind them, and cellular therapies point toward an even more personalized future. SurvivingBreastCancer.org Editorial EDUCATION | IMMUNOTHERAPY Key Takeaways Immunotherapy helps the immune system identify and attack breast cancer cells. Pembrolizumab continues to improve long-term outcomes for some people with triple-negative breast cancer (TNBC). New antibody-drug conjugates give oncologists more ways to treat advanced and metastatic disease. Researchers are studying CAR T-cell therapy and other personalized treatments for breast cancer. Biomarker testing can reveal whether immunotherapy or targeted therapy may fit your diagnosis. Your oncology team can explain how the latest breast cancer treatments apply to your individual care plan. A breast cancer diagnosis brings a flood of new vocabulary, and immunotherapy often tops the list of confusing terms. Put simply, immunotherapy trains your immune system to recognize and attack cancer cells, rather than relying solely on chemotherapy or radiation. For individuals and loved ones navigating treatment decisions in 2026, several genuine breakthroughs deserve attention. Checkpoint Inhibitors Keep Proving Their Worth Cancer cells can sometimes avoid detection by using proteins that act as “off switches” on immune cells. Immune checkpoint inhibitors block those signals, allowing the immune system to respond more effectively. According to the National Cancer Institute, pembrolizumab, sold under the brand name Keytruda, remains the only immunotherapy drug specifically approved to treat breast cancer. Doctors generally use it in combination with other medications rather than on its own. Seven-year follow-up data from the KEYNOTE-522 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showed encouraging results: pairing pembrolizumab with chemotherapy before surgery, then continuing it afterward, improved both distant disease-free survival and overall survival in high-risk, early-stage TNBC patients. That long-term data matters enormously: it shows oncologists and patients that the benefit holds up not just in the months after treatment, but years later. Researchers selected TNBC for early immunotherapy trials because this subtype tends to respond better to immune-based approaches than hormone-receptor-positive cancers do. If you or a loved one has been diagnosed with TNBC, ask your oncology team directly whether checkpoint inhibitor therapy fits your treatment plan. Antibody-Drug Conjugates Pair Up With Immunotherapy Antibody-drug conjugates, or ADCs, deliver chemotherapy directly to cancer cells while sparing healthy tissue. In 2026, these drugs made real strides in metastatic TNBC. The FDA approved Dato-DXd for metastatic TNBC patients who don’t qualify for immunotherapy. The combination of Dato-DXd and a newer ADC called iza-bren improved both progression-free and overall survival compared with standard chemotherapy. Oncologists increasingly combine ADCs with immunotherapy drugs, giving patients more options when a single approach falls short. Cellular Therapies Enter the Picture CAR T-cell therapy has transformed treatment for certain blood cancers, and researchers are now testing it for breast cancer, too. Early-phase trials target antigens such as HER2, ROR1, MUC1, mesothelin, and B7-H3. These trials remain in their infancy, and scientists still face real obstacles, including finding antigens unique enough to breast tumors and overcoming the tumor’s ability to suppress immune attacks. Keep an eye on this research; it represents one of the field’s most promising long-term directions. A New Kind of Targeted Drug Joins the Toolkit May 2026 brought approval of vepdegestrant, sold as Veppanu, the first-ever approved PROTAC protein degrader, for patients with ESR1-mutated, hormone-receptor-positive, HER2-negative advanced breast cancer. While not a traditional immunotherapy, this drug works alongside immune-based treatments in many individuals’ broader care plans and signals how quickly the treatment landscape keeps shifting. What This Means for You Every advance above shares a common thread: oncologists increasingly combine tools rather than relying on any single treatment. Immunotherapy, ADCs, targeted therapies, and even AI-driven screening now work together to catch cancer earlier and treat it more precisely. Treatment jargon can be confusing. Bring a list of questions to every oncology appointment, and don’t hesitate to ask your care team to explain terms in plain language. Ask specifically whether biomarker testing, such as PD-L1 status, could open up immunotherapy options for your specific diagnosis. Breast cancer treatment in 2026 looks meaningfully different than it did even five years ago. Checkpoint inhibitors now come with years of survival data behind them, ADCs give oncologists new ways to target hard-to-treat cancers, and cellular therapies point toward an even more personalized future. Talk with your oncologist about which of these advances might apply to your situation, and remember that research keeps moving forward every single month. Count On Us For additional support navigating your diagnosis, treatment decisions, and life after a breast cancer diagnosis, visit SurvivingBreastCancer.org, which offers programs and trusted educational resources on symptoms, testing, treatment options, surgery, and more, plus podcasts featuring professionals, advocates, and caregivers. Your support helps SurvivingBreastCancer.org continue providing knowledge, connection, and community to those impacted by breast cancer, every day, all year long. Note: This article is designed to provide general information and is not meant to replace professional medical advice. Always discuss your options with your healthcare provider. Watch on YouTube: How MBC Treatments Target Cancer Cells Read More: The Role of Hormones in Breast Cancer Understanding Your Pathology Report: A Comprehensive Step-By-Step Guide AI Advances in Breast Cancer Detection and Treatment On the Podcast: Breast Cancer Conversations Episode 202. Good News for Triple Negative Breast Cancer: A Vaccine and Hope for the Future Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

Subscribe to the Surviving Breast Cancer newsletter for updates on community support, programs, content, and medical breakthroughs for breast cancer patients. Subscribe to Our Mailing List & Never Miss a Beat! Join Thanks for subscribing!

S urvivingB reastC ancer.org (SBC) Bridging the gap between clinical care and everyday life through trusted education, personalized navigation, support, wellness programming, and financial wraparound services from day one and beyond Tell Cancer To Take A Hike Support Our Work (Donate) Join Our Mailing List EXPERIENCE Support Groups Yoga & PIlates Art Expression Expressive Writing Webinars Podcast All Programs Stories READ Blog Articles Submit Content Paid Research Study ENGAGE Shop SBC's Store SHOP TAKE A HIKE MERCH The Quiet Companion BCAM GIVES BACK BCAM: Madam Glam

Explore free breast cancer webinars from SurvivingBreastCancer.org featuring trusted, patient-friendly education from oncologists, clinicians, researchers, wellness experts, and people with lived experience. Our webinars cover topics across the breast cancer continuum, including newly diagnosed support, treatment options, metastatic breast cancer, side effects, survivorship, mental health, integrative wellness, nutrition, movement, and more. Breast Cancer Webinars Learn. Ask Questions. Stay Informed. Expert-led, free virtual education for early-stage and metastatic breast cancer. Upcoming Webinars Multiple Dates Triage Cancer: Make the Most of Medicare Open Enrollment Tue, Oct 13 webinar Triage Cancer Conferences cover key tips to help navigate legal and practical issues, reduce the financial burden of a cancer diagnosis, and lower stress. Share RSVP Breast Cancer and the Inner Critic: How to Change Negative Self-Talk Thu, Oct 29 Zoom Struggling with your inner critic after cancer? Join this powerful 60-minute workshop to learn how to recognize and shift the mental patterns that drain your energy. Share RSVP